Panbela Therapeutics (NASDAQ:PBLA) Stock Price Down 9.1% – Should You Sell?

Panbela Therapeutics, Inc. (NASDAQ:PBLA) fell 9.1% during trading on Friday . The company traded as low as $0.39 and last traded at $0.41. 2,947 shares traded hands during trading, a decline of 89% from the average session volume of 27,623 shares. The stock had previously closed at $0.45.

Panbela Therapeutics Trading Down 9.1 %

The stock has a market capitalization of $1.99 million, a P/E ratio of -0.01 and a beta of 1.56. The stock’s 50 day simple moving average is $0.34 and its 200 day simple moving average is $0.35.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.